[Edaily Starin, Reporter Choi Hee-jae ] Director Christopher Nolan’s film “The Martian” has held the top spot at the box office for a month. “Spider-Man: A Brand New Day” ceded the No. 2 spot to “Obsession.” Poster for the movie “The Odyssey” (Photo courtesy of Universal Pictures) According to the Korean Film Council’s integrated computer network on the 4th, “The Martian” took the No. 1 spot at the box office on the 3rd, drawing 98,412 viewers. Its cumulative audience total stands at 9,329,612. The horror film “Obsession,” which opened on the 2nd, took second place, edging out “Spider-Man: A Brand New Day” (Spider-Man 4). “Obsession” drew 21,759 viewers, bringing its cumulative total to 46,653. Following its debut at the top of the box office, “Spider-Man 4”—which has consistently held the No. 2 spot since the release of “The Odyssey”—drew 19,225 viewers that day. Its cumulative attendance stands at 8,645,360. In fourth place was the film “Bi-gwang,” starring Ryu Seung-ryong and Ha Ji-won, which drew 12,726 viewers. In fifth place was the film “Gyeongju Journey,” starring Lee Jung-eun, Gong Hyo-jin, Park So-dam, and Lee Yeon, which recorded 9,678 viewers. “The Odyssey” continues to dominate in advance ticket sales as well. As of 8:13 a.m. on the 4th, “The Odyssey” had sold 404,925 tickets, maintaining a significant lead over the second-place film. “The Intern,” set to open on the 16th, took second place, while “The Assassin(s),” set to open on the 23rd, took third. Following them, “Spider-Man 4” and “Obsession” ranked fourth and fifth, respectively. Given that “Odyssey” has maintained high advance ticket sales even a month after its release, attention is focused on whether it will surpass the 10-million-viewer mark this weekend.
On the sixth anniversary of the passing of the late Lee Kun-Hee, former chairman of SamsungElectronics, Jay Y. Lee and executives from major affiliate companies gathered at the family cemetery in Suwo…
Aptabio Therapeutics Inc.(293780)has expressed confidence ahead of the announcement of the efficacy of its kidney disease treatment candidate “Isuzinaxib” (APX-115). This follows the company’s selecti…
#Orum Therapeutics, Inc. has reappointed a U.S. business development (BD) expert to its board of directors and expanded the limit on stock options granted to U.S. employees. At an investor briefing he…